Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 1/20 | 0.38 |
| ▸ | HTR1D | P28221 | 4/20 | 0.33 |
| ▸ | HTR1B | P28222 | 4/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.32 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.32 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.31 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.31 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6486457 | 0.89 | AVPR2 (0.46) | AVPR2SLC22A12AVPR1APDCD1CD274 | |
| SCHEMBL5784718 | 0.88 | AVPR2 (0.38) | AVPR2HTR1DHTR1BHTR2AGPBAR1 | |
| Hydrochloric Acid SCHEMBL5785727 | 0.87 | AVPR2 (0.38) | AVPR2HTR1DHTR1BHTR2AGPBAR1 | |
| SCHEMBL6474958 | 0.87 | AVPR2 (0.38) | AVPR2HTR1DHTR1BHTR2AGPBAR1 | |
| SCHEMBL6484549 | 0.85 | AVPR2 (0.48) | AVPR2AVPR1A | |
| SCHEMBL6475175 | 0.85 | AVPR2 (0.48) | AVPR2AVPR1A | |
| SCHEMBL6482881 | 0.84 | AVPR2 (0.40) | AVPR2HTR1DHTR1BHTR2AAVPR1A | |
| SCHEMBL6475645 | 0.83 | AVPR2 (0.46) | AVPR2SLC22A12AVPR1A | |
| SCHEMBL6484499 | 0.83 | AVPR1A (0.38) | AVPR2AVPR1A | |
| SCHEMBL6482669 | 0.82 | AVPR2 (0.40) | AVPR2AVPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6900200-B2 | Tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH (US) | 2005-05-31 | — | — | US | claimed |
| US-20030018026-A1 | Novel tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH (US) | 2003-01-23 | — | — | US | claimed |
| US-6900200-B2 | Tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH (US) | 2005-05-31 | — | — | US | disclosed |
| EP-1377583-A1 | NOVEL TRICYCLIC HYDROXY CARBOXAMIDES AND DERIVATIVES THEREOF; TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | Wyeth (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20030018026-A1 | Novel tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | WYETH (US) | 2003-01-23 | — | — | US | disclosed |
| WO-2002083680-A1 | NOVEL TRICYCLIC HYDROXY CARBOXAMIDES AND DERIVATIVES THEREOF TOCOLYTIC OXYTOCIN RECEPTOR ANTAGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018026-A1 | Novel tricyclic hydroxy carboxamides and derivatives thereof tocolytic oxytocin receptor antagonists | OXTR, OPRL1, HCRTR2 | AVPR2 45/4885HTR1D 40/4885HTR1B 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.